# Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics

> **NCT00994253** · PHASE4 · WITHDRAWN · sponsor: **Corewell Health East**

## Conditions studied

- Hypertension
- Diabetes Type 2

## Interventions

- **DRUG:** Aliskiren
- **DRUG:** Hydrochlorothiazide

## Key facts

- **NCT ID:** NCT00994253
- **Lead sponsor:** Corewell Health East
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-08
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to safety concerns re: the concomitant use of aliskiren with an ACEi or ARB.
- **Last updated:** 2017-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00994253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00994253, "Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00994253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*